BACKGROUND Thrombolysis for acute ischemic stroke has remained controversial. The Canadian Alteplase for Stroke Effectiveness Study, a national prospective cohort study, was conducted to assess the effectiveness of alteplase therapy for ischemic stroke in actual practice. METHODS The study was mandated by the federal government as a condition of licensure of alteplase for the treatment of str...

Background: Sex differences in treatment response to intravenous thrombolysis (IVT) are poorly characterized. We compared sex-disaggregated outcomes patients receiving IVT for acute ischemic stroke the Alteplase Tenecteplase (AcT) trial, a Canadian multicentre, randomised trial. Methods: In this post-hoc analysis, primary outcome was excellent functional (modified Rankin Score [mRS] 0-1) at 90 ...

BACKGROUND Automatic noninvasive oscillometric blood pressure (NIBP) devices measure mean arterial (MAP); systolic and diastolic (SBP, DBP) are algorithmically derived from MAP. The most invalid NIBP is SBP, yet stroke practitioners use it to manage (BP) in accordance with thrombolysis guidelines. We determined agreement between DBP, MAP measured manually by patients treated alteplase. METHODS ...


 Evidence was summarized to determine the effect of alteplase in adult stroke patients.
 There is substantial uncertainty concerning evidence due risk bias available studies and imprecision how magnitude treatment effects were estimated.
 The identified research suggests that administered within 3 hours a might result in:
 fewer deaths after 18 months little-to-no differenc...

Do Not Substitute: IV Thrombolytic Selection Errors in Acute Stroke To the Editor: Activase (alteplase), commonly referred to as tPA, is a tissue-type plasminogen activator approved for treatment of ischemic stroke when given within 3 hours of symptom onset. Of the 6 thrombolytic drugs licensed for any use in the United States, Retaplase (reteplase), and TNKase (tenecteplase) share this mechani...

1 Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013; published online April 23. DOI:10.1007/s40265-0130030-6. 2 Barkhof F, Simon JH, Fazekas F, et al. MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol 2011; 8: 13–21. 3 Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potentia...